(PDF) Translational Research Methods in Diabetes, Obesity 2nd Ed by Andrew J. Krentz
$18.00
Download instantly Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease – A Focus on Early Phase Clinical Drug Development 2nd Edition by Andrew J. Krentz, Christian Weyer, Marcus Hompesch. It is ebook in PDF format.
ISBN-10: 3030117472 ISBN-13: 9783030117474
This is the PDF eBook version for Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease – A Focus on Early Phase Clinical Drug Development 2nd Edition by Andrew J. Krentz, Christian Weyer, Marcus Hompesch
Table of Contents
Part 1: Review of Clinical Investigative Methods
Chapter 1: Quantifying Insulin Action in Humans
Chapter 2: Assessment of Islet Alpha- and Beta-Cell Function
Chapter 3: Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins
Chapter 4: Measurement of Energy Expenditure
Chapter 5: QUANTIFYING APPETITE AND SATIETY
Chapter 6: Non-invasive quantitative magnetic resonance imaging and spectroscopic biomarkers in nonalcoholic fatty liver disease and other cardiometabolic diseases associated with ectopic fat deposition
Chapter 7: Structural and Functional Imaging of Muscle, Heart, Endocrine Pancreas and Kidneys in Cardiometabolic Drug Development
Chapter 8: Positron emission tomography and computed tomography measurement of brown fat thermal activation: key tool for developing novel pharmacotherapeutics for obesity and diabetes
Chapter 9: Isotopic Tracers for the Measurement of Metabolic Flux Rates
Chapter 10: Role of Tissue Biopsy in Drug Development for NonAlcoholic Fatty Liver Disease and Other Metabolic Disorders
Chapter 11: Utility of Invasive and Non-invasive Cardiovascular Research Methodologies in Drug Development for Diabetes, Obesity and NAFLD/NASH
Chapter 12: Omics: Potential role in early phase drug development
Part 2: Preclinical Drug Development and Transitioning to Clinical Studies
Chapter 13: Peptide Drug Design for Diabetes & Related Metabolic Diseases
Chapter 14: ANIMAL MODELS OF TYPE 2 DIABETES, OBESITY AND NONALCOHOLIC STEATOHEPATITIS – CLINICAL TRANSLATABILITY AND APPLICABILITY IN PRECLINICAL DRUG DEVELOPMENT
Chapter 15: Drug Development for Diabetes Mellitus: Beyond Hemoglobin A1c
Chapter 16: Emerging Circulating Biomarkers For The Diagnosis And Assessment Of Treatment Responses In Patients With Hepatic Fat Accumulation, Nash And Liver Fibrosis
Chapter 17: Quantitative Approaches in Translational Cardiometabolic Research:
An Overview
Chapter 18: Transitioning from Preclinical to Clinical Drug Development
Chapter 19: Regulatory Considerations for Early Study and Clinical Development of Drugs for Diabetes, Obesity, NonAlcoholic Steatohepatitis (NASH) and other Cardiometabolic Disorders
Chapter 20: Early Phase Metabolic Research with Reference to Special Populations
